238 related articles for article (PubMed ID: 31909763)
61. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
[TBL] [Abstract][Full Text] [Related]
62. Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets.
Jang M; Simoens S; Kwon T
BioDrugs; 2021 Jan; 35(1):89-101. PubMed ID: 33368051
[TBL] [Abstract][Full Text] [Related]
63. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
[TBL] [Abstract][Full Text] [Related]
64. Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar.
Goyal P; Iyer J; Adhikary L; Vats B; Kabadi P; Pai H; Ranayhossaini D; Gouda S; Subbarao M; Mehta G; Saha A; Bera A; Sahu A; Kaur M; Singh A; Marwah A; Reddy Moole PK; Smith J; Melarkode R; Ullanat R
Future Med Chem; 2021 Sep; 13(18):1531-1557. PubMed ID: 34289749
[No Abstract] [Full Text] [Related]
65. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract][Full Text] [Related]
66. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
Dent S; Ammendolea C; Christofides A; Edwards S; Incekol D; Pourmirza B; Kfoury S; Poirier B
Curr Oncol; 2019 Feb; 26(1):e70-e80. PubMed ID: 30853812
[TBL] [Abstract][Full Text] [Related]
67. Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab.
Franken M; Kanters T; Coenen J; de Jong P; Jager A; Groot CU
Breast; 2020 Aug; 52():71-77. PubMed ID: 32447129
[TBL] [Abstract][Full Text] [Related]
68. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
Leung JH; Tai YS; Wang SY; Yip Fion HT; Tsung-Chin H; Chan AL
Breast; 2022 Oct; 65():91-97. PubMed ID: 35870421
[TBL] [Abstract][Full Text] [Related]
69. Subcutaneous auto-administration of trastuzumab following therapeutic education: A case report.
Deppenweiler M; Debled M; Robquin JL; Lortal-Canguilhem B
J Oncol Pharm Pract; 2019 Sep; 25(6):1523-1525. PubMed ID: 30126339
[TBL] [Abstract][Full Text] [Related]
70. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
71. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
Paplomata E; Nahta R
Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
[TBL] [Abstract][Full Text] [Related]
72. Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study.
Fallowfield L; Osborne S; Langridge C; Monson K; Kilkerr J; Jenkins V
Breast; 2015 Apr; 24(2):166-70. PubMed ID: 25623753
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Yeo W; Luk MY; Soong IS; Yuen TY; Ng TY; Mo FK; Chan K; Wong SY; Tsang J; Leung C; Suen JJ; Ngan RK
Hong Kong Med J; 2018 Feb; 24(1):56-62. PubMed ID: 29326401
[TBL] [Abstract][Full Text] [Related]
74. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
Blackwell K; Gligorov J; Jacobs I; Twelves C
Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
[TBL] [Abstract][Full Text] [Related]
75. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J; Ataseven B; Verrill M; De Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X;
Eur J Cancer; 2017 Sep; 82():237-246. PubMed ID: 28625777
[TBL] [Abstract][Full Text] [Related]
76. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Shparyk Y; Moiseyenko V; Bello M; Semiglazov V; Lee Y; Lim J
Eur J Cancer; 2018 Apr; 93():19-27. PubMed ID: 29448072
[TBL] [Abstract][Full Text] [Related]
77. Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.
Jeon C; Kang SH; Kim SB; Paik NS; Lee I; Kim SK; Kim EY; Son GS; Yoo YB; Lee KH; Shin J; Ju S; Jang H; Park MH
Oncology; 2024; 102(6):465-475. PubMed ID: 37899039
[TBL] [Abstract][Full Text] [Related]
78. How can biosimilars change the trajectory of breast cancer therapy?
Trapani D; Curigliano G
Expert Rev Anticancer Ther; 2020 May; 20(5):325-328. PubMed ID: 32298188
[No Abstract] [Full Text] [Related]
79. [Assessment of Efficacy and Adverse Effects of Trastuzumab Biosimilar in Gastric Cancer].
Okuda Y; Mikame Y; Shinada M; Yamaguchi H; Fujii H; Sudoh T
Gan To Kagaku Ryoho; 2020 Sep; 47(9):1341-1344. PubMed ID: 33130696
[TBL] [Abstract][Full Text] [Related]
80. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
